(MedPage Today) — Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials.
The AKT inhibitor afuresertib failed to improve progression-free survival (PFS) when added to paclitaxel for patients with…
Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114677
Author :
Publish date : 2025-03-16 20:04:00
Copyright for syndicated content belongs to the linked Source.
